Biogen Inc. (BIIB)
New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings
Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of its Feb. 6 report.
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status
BIIB secures FDA's Breakthrough Therapy status for litifilimab in cutaneous lupus, backed by phase II results, while advancing phase III and broader lupus studies.
Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge
Biogen Inc. shares, despite retail investor pessimism, rose 15.1% in 2025. Besides the successful launch of Leqembi, I highlight Skyclarys, an Nrf2 activator for the treatment of Friedreich's ataxia, as a driver of Biogen's EBIT growth. Its sales totaled $132.9 million in Q3, up 29.9% year-over-year.
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
Biogen shares could climb on Leqembi uptake – Jefferies
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) could see its stock move higher over the next two years as progress on its Alzheimer's drug Leqembi and a series of late-stage pipeline readouts draw more investor attention, according to Jefferies. The broker, which rates the stock Buy with a price target of $210, said Leqembi's trajectory in early Alzheimer's disease “could accelerate” if a subcutaneous induction version wins approval in mid-2026, enabling full at-home use.
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript
Biogen Inc. ( BIIB ) TD Cowen Immunology and Inflammation Summit November 13, 2025 4:30 PM EST Company Participants Diana Gallagher Conference Call Participants Philip Nadeau - TD Cowen, Research Division Presentation Philip Nadeau TD Cowen, Research Division Good afternoon, and welcome once again to TD Cowen's 2025 I&I Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Biogen.
Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript
Biogen Inc. ( BIIB ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - Executive VP & Head of Development Alisha Alaimo - President & Head of North America Robin Kramer - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Evan Seigerman - BMO Capital Markets Equity Research Salveen Richter - Goldman Sachs Group, Inc., Research Division Brian Abrahams - RBC Capital Markets, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Marc Goodman - Leerink Partners LLC, Research Division Lin Tsai - Jefferies LLC, Research Division Terence Flynn - Morgan Stanley, Research Division David Amsellem - Piper Sandler & Co., Research Division Presentation Operator Good morning. My name is Cynthia, and I will be your conference operator today.
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
